Symbols / CNTX
CNTX Chart
About
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 227.86M |
| Enterprise Value | 151.06M | Income | -26.44M | Sales | — |
| Book/sh | 0.80 | Cash/sh | 0.84 | Dividend Yield | — |
| Payout | 0.00% | Employees | 12 | IPO | — |
| P/E | — | Forward P/E | -5.78 | PEG | — |
| P/S | — | P/B | 3.12 | P/C | — |
| EV/EBITDA | -5.00 | EV/Sales | — | Quick Ratio | 12.75 |
| Current Ratio | 13.10 | Debt/Eq | 0.19 | LT Debt/Eq | — |
| EPS (ttm) | -0.24 | EPS next Y | -0.43 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-05 16:00 | ROA | -22.81% |
| ROE | -33.68% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 91.88M |
| Shs Float | 42.72M | Short Float | 0.94% | Short Ratio | 0.29 |
| Short Interest | — | 52W High | 2.85 | 52W Low | 0.49 |
| Beta | 1.95 | Avg Volume | 1.51M | Volume | 783.94K |
| Target Price | $5.62 | Recom | Strong_buy | Prev Close | $2.28 |
| Price | $2.48 | Change | 8.77% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$5.63
Mean price target
2. Current target
$2.48
Latest analyst target
3. DCF / Fair value
$-2.90
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.48
Low
$4.00
High
$9.00
Mean
$5.63
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-22 | init | Jones Trading | — → Buy | $7 |
| 2025-11-06 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-11-06 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-10-16 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-10-02 | init | Cantor Fitzgerald | — → Overweight | — |
| 2025-09-18 | init | Guggenheim | — → Buy | $5 |
| 2025-08-07 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-08-07 | main | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-06-26 | reit | Piper Sandler | Overweight → Overweight | $4 |
| 2025-05-08 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-04-29 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-04-21 | init | William Blair | — → Outperform | — |
| 2025-04-09 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-03-21 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-03-21 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-01-15 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-01-08 | init | JMP Securities | — → Market Outperform | $4 |
| 2024-11-25 | init | D. Boral Capital | — → Buy | $9 |
| 2024-09-23 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-09-16 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
- Context Therapeutics Insiders May Regret Not Buying More, Market Cap Hits US$151m - simplywall.st Fri, 23 Jan 2026 08
- LifeSci Capital Initiates Context Therapeutics(CNTX.US) With Buy Rating, Announces Target Price $6 - 富途牛牛 Wed, 25 Feb 2026 04
- Biotech firm Context Therapeutics lines up four investor conferences - Stock Titan Mon, 09 Feb 2026 08
- Here's Why We're Not Too Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Situation - Yahoo Finance hu, 05 Feb 2026 08
- New Analyst Forecast: $CNTX Given 'Buy' Rating - Quiver Quantitative hu, 16 Oct 2025 07
- Guggenheim Initiates Coverage of Context Therapeutics (CNTX) with Buy Recommendation - Nasdaq hu, 18 Sep 2025 07
- Context Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire Mon, 09 Feb 2026 12
- Institutions profited after Context Therapeutics Inc.'s (NASDAQ:CNTX) market cap rose US$14m last week but private equity firms profited the most - Yahoo Finance Wed, 08 Oct 2025 07
- Context Therapeutics: Undervalued Cancer Fighter (NASDAQ:CNTX) - Seeking Alpha ue, 10 Jun 2025 07
- Context Therapeutics Highlights T Cell Engager Pipeline Strategy - TipRanks hu, 08 Jan 2026 08
- We're Hopeful That Context Therapeutics (NASDAQ:CNTX) Will Use Its Cash Wisely - simplywall.st Fri, 19 Dec 2025 08
- Context Therapeutics (NASDAQ: CNTX) Issues Equity Awards to Attract New Talent - MyChesCo hu, 22 Jan 2026 08
- Context Therapeutics Inc. Reports Encouraging Phase 1 Trial Results for CTIM-76 and CT-95, Financial Update for Q3 2025 - Quiver Quantitative Wed, 05 Nov 2025 08
- Jones Trading Initiates Coverage of Context Therapeutics (CNTX) with Buy Recommendation - Nasdaq Mon, 22 Dec 2025 08
- Is Context Therapeutics (NASDAQ:CNTX) In A Good Position To Invest In Growth? - Yahoo Finance Fri, 29 Aug 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 100000 | 70080 | — | Purchase at price 0.70 per share. | LEHR MARTIN A | Chief Executive Officer | — | 2025-06-09 00:00:00 | I |
| 1 | 40010 | 25486 | — | Purchase at price 0.64 per share. | MINAI-AZARY JENNIFER LYNN | Chief Financial Officer | — | 2025-06-06 00:00:00 | D |
| 2 | 20000 | 11520 | — | Purchase at price 0.58 per share. | LEVIT ALEX C. | Officer | — | 2025-06-06 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -29.91M | -25.06M | -14.37M | -7.31M |
| TotalUnusualItems | 0.00 | -500.00K | -3.08M | |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -500.00K | -3.08M | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -26.73M | -23.96M | -14.84M | -10.46M |
| ReconciledDepreciation | 10.88K | 12.04K | 9.27K | 0.00 |
| EBITDA | -29.91M | -25.06M | -14.87M | -10.39M |
| EBIT | -29.92M | -25.07M | -14.88M | -10.39M |
| NetInterestIncome | 3.20M | 1.16M | 547.27K | -64.24K |
| InterestExpense | 64.24K | |||
| InterestIncome | 3.20M | 1.16M | 547.27K | |
| NormalizedIncome | -26.73M | -23.96M | -14.34M | -7.38M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -26.73M | -23.96M | -14.84M | -10.46M |
| TotalExpenses | 29.92M | 25.07M | 14.88M | 7.44M |
| TotalOperatingIncomeAsReported | -29.92M | -25.07M | -15.38M | -10.53M |
| DilutedAverageShares | 58.42M | 15.97M | 15.97M | 2.83M |
| BasicAverageShares | 58.42M | 15.97M | 15.97M | 2.83M |
| DilutedEPS | -0.46 | -1.50 | -0.93 | -3.69 |
| BasicEPS | -0.46 | -1.50 | -0.93 | -3.69 |
| DilutedNIAvailtoComStockholders | -26.73M | -23.96M | -14.84M | -10.46M |
| NetIncomeCommonStockholders | -26.73M | -23.96M | -14.84M | -10.46M |
| NetIncome | -26.73M | -23.96M | -14.84M | -10.46M |
| NetIncomeIncludingNoncontrollingInterests | -26.73M | -23.96M | -14.84M | -10.46M |
| NetIncomeContinuousOperations | -26.73M | -23.96M | -14.84M | -10.46M |
| PretaxIncome | -26.73M | -23.96M | -14.84M | -10.46M |
| OtherIncomeExpense | -1.43K | -55.57K | -502.00K | -2.95M |
| OtherNonOperatingIncomeExpenses | -1.43K | -55.57K | -2.00K | 123.87K |
| SpecialIncomeCharges | 0.00 | -500.00K | -3.09M | |
| OtherSpecialCharges | 500.00K | 3.09M | ||
| RestructuringAndMergernAcquisition | 3.09M | |||
| GainOnSaleOfSecurity | 9.32K | |||
| NetNonOperatingInterestIncomeExpense | 3.20M | 1.16M | 547.27K | -64.24K |
| InterestExpenseNonOperating | 64.24K | |||
| InterestIncomeNonOperating | 3.20M | 1.16M | 547.27K | |
| OperatingIncome | -29.92M | -25.07M | -14.88M | -7.44M |
| OperatingExpense | 29.92M | 25.07M | 14.88M | 7.44M |
| ResearchAndDevelopment | 22.70M | 17.78M | 7.09M | 3.81M |
| SellingGeneralAndAdministration | 7.22M | 7.29M | 7.79M | 3.63M |
| GeneralAndAdministrativeExpense | 7.22M | 7.29M | 7.79M | 3.63M |
| OtherGandA | 7.22M | 7.29M | 7.79M | 3.63M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 89.70M | 15.97M | 15.97M | 15.97M |
| ShareIssued | 89.70M | 15.97M | 15.97M | 15.97M |
| TotalDebt | 219.38K | 0.00 | 55.08K | 0.00 |
| TangibleBookValue | 95.27M | 11.87M | 34.76M | 48.27M |
| InvestedCapital | 95.27M | 11.87M | 34.76M | 48.27M |
| WorkingCapital | 95.15M | 11.86M | 34.65M | 48.22M |
| NetTangibleAssets | 95.27M | 11.87M | 34.76M | 48.27M |
| CapitalLeaseObligations | 219.38K | 0.00 | 55.08K | 0.00 |
| CommonStockEquity | 95.27M | 11.87M | 34.76M | 48.27M |
| TotalCapitalization | 95.27M | 11.87M | 34.76M | 48.27M |
| TotalEquityGrossMinorityInterest | 95.27M | 11.87M | 34.76M | 48.27M |
| StockholdersEquity | 95.27M | 11.87M | 34.76M | 48.27M |
| RetainedEarnings | -94.78M | -68.05M | -44.09M | -29.25M |
| AdditionalPaidInCapital | 189.96M | 79.91M | 78.83M | 77.51M |
| CapitalStock | 89.70K | 15.97K | 15.97K | 15.97K |
| CommonStock | 89.70K | 15.97K | 15.97K | 15.97K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 2.86M | 4.19M | 3.21M | 3.03M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 112.06K | 0.00 | 0.00 | 0.00 |
| PreferredSecuritiesOutsideStockEquity | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 112.06K | 0.00 | ||
| LongTermCapitalLeaseObligation | 112.06K | 0.00 | ||
| CurrentLiabilities | 2.75M | 4.19M | 3.21M | 3.03M |
| OtherCurrentLiabilities | 49.78K | 8.49K | 83.46K | 85.53K |
| CurrentDebtAndCapitalLeaseObligation | 107.32K | 55.08K | ||
| CurrentCapitalLeaseObligation | 107.32K | 0.00 | 55.08K | 0.00 |
| PensionandOtherPostRetirementBenefitPlansCurrent | 891.92K | 652.80K | 770.05K | 436.99K |
| PayablesAndAccruedExpenses | 1.70M | 3.53M | 2.30M | 2.51M |
| CurrentAccruedExpenses | 247.23K | 1.15M | 1.36M | 684.60K |
| Payables | 1.45M | 2.38M | 936.33K | 1.83M |
| AccountsPayable | 1.45M | 2.38M | 936.33K | 1.83M |
| TotalAssets | 98.13M | 16.06M | 37.97M | 51.31M |
| TotalNonCurrentAssets | 230.78K | 15.52K | 112.28K | 50.39K |
| OtherNonCurrentAssets | 32.75K | 50.39K | ||
| NonCurrentDeferredAssets | 0.00 | |||
| NetPPE | 230.78K | 15.52K | 79.53K | 0.00 |
| GrossPPE | 230.78K | 15.52K | 79.53K | 0.00 |
| OtherProperties | 230.78K | 15.52K | 79.53K | |
| CurrentAssets | 97.90M | 16.05M | 37.85M | 51.26M |
| OtherCurrentAssets | 3.47M | 1.60M | 2.36M | 1.62M |
| PrepaidAssets | 1.62M | |||
| CashCashEquivalentsAndShortTermInvestments | 94.43M | 14.45M | 35.50M | 49.64M |
| CashAndCashEquivalents | 94.43M | 14.45M | 35.50M | 49.64M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -29.31M | -21.05M | -14.09M | -9.05M |
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 109.29M | 0.00 | 0.00 | 58.39M |
| CapitalExpenditure | -14.76M | -536.84K | -250.00K | |
| EndCashPosition | 94.43M | 14.45M | 35.50M | 49.69M |
| BeginningCashPosition | 14.45M | 35.50M | 49.69M | 341.04K |
| ChangesInCash | 79.98M | -21.05M | -14.19M | 49.34M |
| FinancingCashFlow | 109.29M | 0.00 | -102.07K | 58.39M |
| CashFlowFromContinuingFinancingActivities | 109.29M | 0.00 | -102.07K | 58.39M |
| NetOtherFinancingCharges | -102.07K | |||
| NetPreferredStockIssuance | 0.00 | 4.98M | ||
| PreferredStockIssuance | 0.00 | 4.98M | ||
| NetCommonStockIssuance | 109.29M | 0.00 | 0.00 | 53.41M |
| CommonStockIssuance | 109.29M | 0.00 | 0.00 | 53.41M |
| NetIssuancePaymentsOfDebt | 0.00 | |||
| NetLongTermDebtIssuance | 0.00 | |||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -14.76M | 0.00 | -536.84K | -250.00K |
| CashFlowFromContinuingInvestingActivities | -14.76M | 0.00 | -536.84K | -250.00K |
| NetIntangiblesPurchaseAndSale | -14.75M | 0.00 | -500.00K | -250.00K |
| PurchaseOfIntangibles | -14.75M | 0.00 | -500.00K | -250.00K |
| NetPPEPurchaseAndSale | -7.32K | 0.00 | -36.84K | 0.00 |
| PurchaseOfPPE | -7.32K | 0.00 | -36.84K | 0.00 |
| OperatingCashFlow | -14.56M | -21.05M | -13.55M | -8.80M |
| CashFlowFromContinuingOperatingActivities | -14.56M | -21.05M | -13.55M | -8.80M |
| ChangeInWorkingCapital | -3.48M | 1.78M | -277.52K | -2.22M |
| ChangeInOtherCurrentLiabilities | -41.26K | -55.08K | -75.41K | 0.00 |
| ChangeInOtherCurrentAssets | 0.00 | 32.75K | -32.75K | 0.00 |
| ChangeInPayablesAndAccruedExpense | -1.57M | 1.04M | 566.68K | -613.35K |
| ChangeInAccruedExpense | -619.77K | -407.47K | 1.35M | 252.66K |
| ChangeInPayable | -946.10K | 1.45M | -787.89K | -866.01K |
| ChangeInAccountPayable | -946.10K | 1.45M | -787.89K | -866.01K |
| ChangeInPrepaidAssets | -1.87M | 758.83K | -736.05K | -1.61M |
| OtherNonCashItems | 14.75M | 500.00K | 3.12M | |
| StockBasedCompensation | 841.87K | 1.08M | 976.44K | 511.08K |
| DepreciationAmortizationDepletion | 10.88K | 12.04K | 9.27K | 0.00 |
| DepreciationAndAmortization | 10.88K | 12.04K | 9.27K | 0.00 |
| OperatingGainsLosses | 41.82K | 51.97K | 78.52K | 246.32K |
| GainLossOnInvestmentSecurities | 371.89K | |||
| GainLossOnSaleOfPPE | 41.82K | 51.97K | 78.52K | 0.00 |
| NetIncomeFromContinuingOperations | -26.73M | -23.96M | -14.84M | -10.46M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CNTX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|